0001694187-20-000063.txt : 20200506 0001694187-20-000063.hdr.sgml : 20200506 20200506210607 ACCESSION NUMBER: 0001694187-20-000063 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200506 FILED AS OF DATE: 20200506 DATE AS OF CHANGE: 20200506 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Al-Wakeel Yasir B. CENTRAL INDEX KEY: 0001650691 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38551 FILM NUMBER: 20854244 MAIL ADDRESS: STREET 1: MERRIMACK PHARMACEUTICALS, INC. STREET 2: ONE KENDALL SQUARE, SUITE B7201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Neon Therapeutics, Inc. CENTRAL INDEX KEY: 0001694187 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 110 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-337-4701 MAIL ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 110 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 wf-form4_158881354959855.xml FORM 4 X0306 4 2020-05-06 1 0001694187 Neon Therapeutics, Inc. NTGN 0001650691 Al-Wakeel Yasir B. C/O NEON THERAPEUTICS, INC. 40 ERIE STREET, SUITE 110 CAMBRIDGE MA 02139 0 1 0 0 Chief Financial Officer Common Stock 2020-05-06 4 D 0 196965 D 0 D Stock Option (Right to Buy) 5.8 2020-05-06 4 D 0 192759 D Common Stock 192759.0 0 D Stock Option (Right to Buy) 10.2 2020-05-06 4 D 0 61031 D Common Stock 61031.0 0 D Stock Option (Right to Buy) 6.13 2020-05-06 4 D 0 100000 D Common Stock 100000.0 0 D This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. This number includes 154,584 restricted stock units (each, an "RSU") held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). /s/ Jolie M. Siegel, as attorney in fact 2020-05-06